Tier 2 — strong

Targeting inflammation in cardiometabolic disease: Icosapent ethyl modulates monocyte-derived macrophages isolated from patients with cardiovascular disease with or without type 2 diabetes

J. K. Ward, M. U. Shah, K. Lee, P. E. Squires, C. E. Hills
Diabetic Medicine 2026 43(4):e70247

Bibliography

PubMed
PMID 41664438
PubMed Central
PMC12982656
DOI
10.1111/dme.70247
Trial registry
View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Funding
Amarin Global; University of Lincoln
Competing interests
None declared.

Study snapshot

DesignSingle-centre prospective open-label cohort with randomization to immediate versus delayed initiation of licensed icosapent ethyl.
ModelAdults with established atherosclerotic cardiovascular disease, with or without type 2 diabetes, eligible for Vazkepa under standard care.
Sample68 planned (34 per arm)
InterventionVazkepa (icosapent ethyl; IPE), 1.996 g twice daily; immediate initiation versus delayed initiation at day 90.
Duration6 months
EndpointsNLRP3 inflammasome activation in monocyte-derived macrophages; Cellular senescence and SASP signaling; Connexin-43 and ATP-release signaling; Exploratory cardiometabolic and type 2 diabetes subgroup measures

What the study showed, in plain terms

This peer-reviewed registered protocol describes a 68-participant, single-centre, open-label study in adults with established atherosclerotic cardiovascular disease, with or without type 2 diabetes. Participants are randomized to immediate or delayed initiation of licensed icosapent ethyl (Vazkepa), with six months of follow-up and mechanistic macrophage endpoints including NLRP3 inflammasome activation, cellular senescence/SASP and connexin-43/ATP signaling. The paper reports the study design, not efficacy outcomes.

Key findings

The publication establishes a prospectively registered 68-participant design with 34 participants planned per arm, randomized timing of icosapent ethyl initiation, six months of follow-up, and predefined macrophage inflammation and senescence endpoints. It does not report treatment outcomes.

What this study can and cannot tell us

Protocol-only publication with no efficacy or safety results. The study is single-centre and open-label, with no placebo control. Randomization concerns immediate versus delayed treatment initiation, so the protocol cannot by itself establish clinical efficacy, safety, or reduction in cardiovascular events.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology